Abstract
Introduction
Carcinoma metastasis to bone is a common reason for consultation to orthopedic surgeons. The presence of bone metastases (BM) is usually associated with poor prognosis which is worsened in the presence of synchronous metastases. The purpose of this study was to: (1) identify the most common carcinomas presenting with BM at diagnosis, to (2) analyze their survival, and (3) compare this against the survival of patients with additional synchronous metastasis based on a large population analysis.
Materials and methods
Patients diagnosed with carcinoma between January 2010 and December 2015 were identified from the Surveillance, Epidemiology and End Results (SEER) database. The most common carcinomas presenting with BM at diagnosis were identified. Survival based on the presence of BM and synchronous metastases (lung, brain, liver, lymph nodes) was evaluated with Kaplan–Meier analysis. Five-year survival (%) stratified by carcinoma type was calculated. Hazard ratio (HR) for mortality comparing isolated BM to other synchronous metastases was performed.
Results
A total of 4.85% of patients (98,606/2,035,204) with carcinoma presented with BM at diagnosis, most commonly from a lung primary. Five-year survival with isolated BM was lowest in patients with pancreatic carcinoma (5.8%, 95% CI 3.0–9.9%), and highest in patients with breast carcinoma (41.1%, 95% CI 38.6–43.5%). Synchronous metastases increased significantly the risk of mortality within the majority of carcinomas.
Conclusion
BM at diagnosis has a poor prognosis which is worsened if synchronous metastases are present; a fact to consider when planning orthopedic interventions.
Level of evidence
Level III, prognostic study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9(3):509–524
Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176
Ibrahim T, Mercatali L, Amadori D (2013) Bone and cancer: the osteoncology. Clin Cases Miner Bone Metab 10(2):121–123
Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184(1):162–167
Hoshi M, Taguchi S, Hayakawa K, Leguchi M, Nakamura H (2011) Evaluation of clinical problems associated with bone metastases from carcinoma from unknown primary sites. Arch Orthop Trauma Surg 131:59–64
Yong M, Jensen AØ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129(2):495–503
Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S (2010) Predictors of survival in patients with prostate cancer and spinal metastasis. J Neurosurg spine 13(6):789–794
Ghosh S, Rao PB (2015) Osseous metastases in gynaecological epithelial malignancies: a retrospective institutional study and review of literature. J Clin Diagn Res 9(12):XC10–XC13
Reinstein ZZ, Pamarthy S, Sagar V, Costa R, Abdulkadir SA, Giles FJ, Carneiro BA (2017) Overcoming immunosuppression in bone metastases. Crit Rev Oncol/Hematol 117:114–127
Yee AJ, Raje NS (2018) Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncol 14(3):195–203
Katzer A, Meenen NM, Grabbe F, Rueger J (2002) Surgery of skeletal metastases. Arch Orthop Trauma Surg 122:251–258
Jehn CF, Diel IJ, Overkamp F, Kurth A, Schaefer R, Miller K, Lüftner D (2016) Management of metastasic bone disease algorithms for diagnostics and treatment. Anticancer Res 36(6):2631–2637
Kondziolka D, Kalkanis SN, Mehta MP, Ahluwalia M, Loeffler JS (2014) It is time to reevaluate the management of patients with brain metastases. Neurosurgery 75(1):1–9
Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME (2016) The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol 40(12):e94–e102
Yu JB, Gross CP, Wilson LD, Smith BD (2009) NCI SEER public-use data: applications and limitations in oncology research. Oncology 23(3):288–295
Funding
No funding was obtained for this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
Ethical approval
As this is a publicly available database, our study was exempt from institutional review board approval.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Younis, M.H., Fuentes-Rivera, L., Summers, S. et al. Survival in patients with carcinomas presenting with bone metastasis at diagnosis: a SEER population-based cohort study. Arch Orthop Trauma Surg 141, 367–373 (2021). https://doi.org/10.1007/s00402-020-03417-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00402-020-03417-3